D. S. Stephens, Conquering the meningococcus, FEMS Microbiol Rev, vol.31, pp.3-14, 2007.

G. Gabutti, A. Stefanati, and P. Kuhdari, Epidemiology of Neisseria meningitidis infections: case distribution by age and relevance of carriage, J Prev Med Hyg, vol.56, pp.116-120, 2015.

L. K. Mcneil, R. J. Zagursky, S. L. Lin, E. Murphy, G. W. Zlotnick et al., Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease, Microbiol Mol Biol Rev, vol.77, pp.234-252, 2013.

N. E. Rosenstein, B. A. Perkins, D. S. Stephens, T. Popovic, and J. M. Hughes, Meningococcal disease, N Engl J Med, vol.344, pp.1378-1388, 2001.

J. Finne, M. Leinonen, and P. H. Mäkelä, Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis, Lancet ii, pp.355-357, 1983.

J. Holst, D. Martin, R. Arnold, C. C. Huergo, P. Oster et al., Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis, Vaccine, vol.27, pp.3-12, 2009.

F. A. Wyle, M. S. Artenstein, B. L. Brandt, E. C. Tramont, D. L. Kasper et al., Immunologic response of man to group B meningococcal polysaccharide vaccines, J Infect Dis, vol.126, pp.514-521, 1972.

L. Bernfield, L. D. Fletcher, A. Howell, J. E. Farley, R. Zagursky et al., Identification of a novel vaccine candidate for group B Neisseria meningitidis, p 116, Abstracts of the Thirteenth International Pathogenic Neisseria Conference, 2002.

L. D. Fletcher, L. Bernfield, V. Barniak, J. E. Farley, A. Howell et al., Vaccine potential of the Neisseria meningitidis 2086 lipoprotein, Infect Immun, vol.72, pp.2088-2100, 2004.

M. C. Schneider, R. M. Exley, H. Chan, I. Feavers, Y. H. Kang et al., Functional significance of factor H binding to Neisseria meningitidis, J Immunol, vol.176, pp.7566-7575, 2006.

S. K. Hoiseth, E. Murphy, L. Andrew, U. Vogel, M. Frosch et al., A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups, Pediatr Infect Dis J, vol.32, pp.1096-1101, 2013.
URL : https://hal.archives-ouvertes.fr/pasteur-02089119

P. K?í?ová, M. Musílek, Z. Vacková, J. Kozáková, H. Claus et al., Predicted strain coverage of a new protein-based meningococcal vaccine in the Czech Republic, Epidemiol Mikrobiol Imunol, vol.63, pp.103-106, 2014.

E. Murphy, L. Andrew, K. L. Lee, D. A. Dilts, L. Nunez et al., Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis, J Infect Dis, vol.200, pp.379-389, 2009.

U. Vogel, M. K. Taha, J. A. Vazquez, J. Findlow, H. Claus et al., Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment, Lancet Infect Dis, vol.13, issue.13, pp.70006-70015, 2013.
URL : https://hal.archives-ouvertes.fr/pasteur-02093031

H. Q. Jiang, S. K. Hoiseth, S. L. Harris, L. K. Mcneil, D. Zhu et al., Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease, Vaccine, vol.28, pp.6086-6093, 2010.

. Anonymous, Trumenba: a serogroup B meningococcal vaccine, Med Lett Drugs Ther, vol.57, pp.5-6, 2015.

H. S. Marshall, P. C. Richmond, M. D. Nissen, A. Wouters, J. Baber et al., A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults, Vaccine, vol.31, pp.1569-1575, 2013.

M. D. Nissen, H. S. Marshall, P. C. Richmond, Q. Jiang, S. L. Harris et al., A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents, Pediatr Infect Dis J, vol.32, pp.364-371, 2013.

P. C. Richmond, H. S. Marshall, M. D. Nissen, Q. Jiang, K. U. Jansen et al., Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial, Lancet Infect Dis, vol.12, pp.70087-70094, 2001.

P. C. Richmond, M. D. Nissen, H. S. Marshall, S. B. Lambert, D. Roberton et al., A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial, Vaccine, vol.30, pp.6163-6174, 2012.

R. Borrow, P. Balmer, and E. Miller, Meningococcal surrogates of protection-serum bactericidal antibody activity, Vaccine, vol.23, pp.2222-2227, 2005.

G. W. Zlotnick, T. R. Jones, P. Liberator, L. Hao, S. Harris et al., The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B fHBP Expression on NmB Isolates ® Disease, Hum Vaccin Immunother, vol.11, pp.5-13, 2015.

S. L. Harris, R. G. Donald, J. C. Hawkins, C. Tan, R. O'neill et al., Neisseria meningitidis serogroup B vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains, Pediatr Infect Dis J, vol.36, pp.216-223, 2017.

R. G. Donald, J. C. Hawkins, L. Hao, P. Liberator, T. R. Jones et al., Meningococcal serogroup B vaccines: estimating breadth of coverage, Hum Vaccin Immunother, vol.13, pp.255-265, 2017.

A. Mascioni, B. E. Bentley, R. Camarda, D. A. Dilts, P. Fink et al., Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086, J Biol Chem, vol.284, pp.8738-8746, 2009.

S. K. Hoiseth, E. Murphy, L. Andrew, K. L. Lee, K. Ambrose et al., LP2086 and MLST distribution in epidemiologically relevant strains of serogroup B Neisseria meningitidis, p P137, Abstracts of the Sixteenth International Pathogenic Neisseria Conference. National Institute of Public Health, 2008.

A. C. Cohn, J. R. Macneil, L. H. Harrison, C. Hatcher, J. Theodore et al., Changes in Neisseria meningitidis disease epidemiology in the United States, Clin Infect Dis, vol.50, pp.184-191, 1998.

X. Wang, A. Cohn, M. Comanducci, L. Andrew, X. Zhao et al., Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States, Vaccine, vol.29, pp.4739-4744, 2011.

M. Diermayer, K. Hedberg, F. Hoesly, M. Fischer, B. Perkins et al., Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain, JAMA, vol.281, pp.1493-1497, 1999.

G. Madico, J. A. Welsch, L. A. Lewis, A. Mcnaughton, D. H. Perlman et al., The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance, J Immunol, vol.177, pp.501-510, 2006.

D. J. Litt, S. Savino, A. Beddek, M. Comanducci, C. Sandiford et al., Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease, J Infect Dis, vol.190, pp.1488-1497, 2004.

D. A. Ala'aldeen, M. Flint, N. J. Oldfield, S. A. Omer, L. K. Mcneil et al., Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage, Vaccine, vol.28, pp.7667-7675, 2010.

S. Jacobsson, P. Mölling, and P. Olcén, Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis, Vaccine, vol.27, pp.5755-5759, 2009.

M. Biagini, M. Spinsanti, D. Angelis, G. Tomei, S. Ferlenghi et al., Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined, Proc Natl Acad Sci U S A, vol.113, pp.2714-2719, 2016.

C. E. Frasch, R. Borrow, and J. Donnelly, Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease, Vaccine, vol.27, issue.2, pp.112-116, 2009.

E. D. Mcintosh, M. Bröker, J. Wassil, J. A. Welsch, and R. Borrow, Serum bactericidal antibody assays-the role of complement in infection and immunity, Vaccine, vol.33, pp.4414-4421, 2015.

C. M. Kahler, L. E. Martin, G. C. Shih, M. M. Rahman, R. W. Carlson et al., The (alpha2¡8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum, Infect Immun, vol.66, pp.5939-5947, 1998.

M. C. Geoffroy, S. Floquet, A. Métais, X. Nassif, and V. Pelicic, Large-scale analysis of the meningococcus genome by gene disruption: resistance to complement-mediated lysis, Genome Res, vol.13, pp.391-398, 2003.

M. G. Müller, N. E. Moe, P. Q. Richards, and G. R. Moe, Resistance of Neisseria meningitidis to human serum depends on T and B cell stimulating protein B, Infect Immun, vol.83, pp.3134-3148, 2015.

M. K. Taha, J. C. Hawkins, P. Liberator, A. E. Deghmane, L. Andrew et al., Bactericidal activity of serums from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France, Vaccine, vol.35, pp.1530-1537, 2017.

L. K. Mcneil, E. Murphy, X. J. Zhao, S. Guttmann, S. L. Harris et al., Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide, Vaccine, vol.27, pp.3417-3421, 2009.

A. F. Winder and W. L. Gent, Correction of light-scattering errors in spectrophotometric protein determinations, Biopolymers, vol.10, pp.1243-1251, 1971.

G. L. Peterson, A simplification of the protein assay method of Lowry et al. which is more generally applicable, Anal Biochem, vol.83, pp.346-356, 1977.

D. Mar, C. Greenbaum, E. A. Mayne, L. Englander, S. W. Woods et al., Structure and properties of alpha-synuclein and other amyloids determined at the amino acid level, Proc Natl Acad Sci U S A, vol.102, pp.15477-15482, 2005.

J. J. Englander, D. Mar, C. Li, W. Englander, S. W. Kim et al., Protein structure change studied by hydrogendeuterium exchange, functional labeling, and mass spectrometry, 2003.

, Proc Natl Acad Sci U S A, vol.100, pp.7057-7062

Y. Hamuro, K. M. Zawadzki, J. S. Kim, D. D. Stranz, S. S. Taylor et al., Dynamics of cAPK type IIbeta activation revealed by enhanced amide H/2H exchange mass spectrometry (DXMS), J Mol Biol, vol.327, pp.234-235, 2003.

D. Pantazatos, J. S. Kim, H. E. Klock, R. C. Stevens, I. A. Wilson et al., Rapid refinement of crystallographic protein construct definition employing enhanced hydrogen-deuterium exchange MS, 2004.

, Proc Natl Acad Sci U S A, vol.101, pp.751-756

V. L. Woods and Y. Hamuro, High resolution, high-throughput amide deuterium exchange-mass spectrometry (DXMS) determination of protein binding site structure and dynamics: utility in pharmaceutical design, J Cell Biochem Suppl, vol.37, pp.89-98, 2001.

A. Gribenko, L. Mosyak, S. Ghosh, K. Parris, K. Svenson et al., Three-dimensional structure and biophysical characterization of Staphylococcus aureus cell surface antigen-manganese transporter MntC, J Mol Biol, vol.425, pp.3429-3445, 2013.

R. Borrow and G. M. Carlone, Serogroup B and C serum bactericidal assays, Methods Mol Med, vol.66, pp.289-304, 2001.

, Standardization and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A/C vaccines, World Health Organization, 1999.